Researchers say the increase in carbapenemase-producing Enterobacterales infection and colonization is being driven by in-hospital transmission.
Colistin is one of the few remaining options for treating multidrug-resistant Klebsiella pneumoniae.
The small pilot trial found fecal microbiota transplantation was safe in long-term acute care hospital patients colonized with multidrug-resistant organisms.
A review and meta-analysis finds shorter antibiotic courses show similar efficacy for bloodstream infections in immunocompetent patients compared with longer courses.
Data from 352 US outpatient facilities show a 20% increase in antibiotic prescribing per year from 2021 through 2023, a finding researchers say reflects a return to pre-pandemic healthcare use patterns.
Researchers in Italy observed a significant reduction in antibiotic use for sexually transmitted infections after the targeted introduction of doxyPEP.
Among hospitalized pneumonia patients, screening for MRSA colonization with a nasal swab-based rapid PCR test cut duration of anti-MRSA antibiotics by 2 days.
Clarametyx Biosciences announced that CMTX-101, a monoclonal antibody designed to collapse bacterial biofilms, will receive priority review and other development incentives from the FDA.
The WHO guidance aims to spur development of in vitro diagnostic tests that can quickly and accurately identify serious bacterial infections in infants and newborns.
Among hospitalized patients in Israel, exposure to any antibiotic was associated with double the risk for C difficile infection.
The FDA has agreed to fast-track its review of gepotidacin, an oral antibiotic already approved for urinary tract infections, for the treatment of uncomplicated gonorrhea.
Data from 412 US hospitals from 2018 through 2023 show 4.5% of patients received an antifungal, a finding researchers say warrants a specific focus on antifungal stewardship.
